Rosuvastatin combined with ramipril significantly reduced atheroma volume by anti-inflammatory mechanism: Comparative analysis with rosuvastatin alone by intravascular ultrasound

International Journal of Cardiology

Volumn 158, Issue 2, 2012, Pages 217-224

  Han, Seung Hwan ^a   Chung, Wook Jin ^a   Kang, Woong Chol ^a   Lee, Kyounghoon ^a   Park, Yae Min ^a   Shin, Mi Seung ^a   Ahn, Tae Hoon ^a   Choi, In Suck ^a   Shin, Eak Kyun ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Angiotensin converting enzyme inhibitor; Coronary artery disease; Intravascular ultrasound; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL STIMULATING AGENT; CHOLESTEROL; CLOPIDOGREL; GELATINASE B; GLUCOSE; INSULIN; LONG ACTING DRUG; NITRATE; ORAL ANTIDIABETIC AGENT; RAMIPRIL; ROSUVASTATIN; SULFONYLUREA;

ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROMA; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; INTRAVASCULAR ULTRASOUND; MALE; METABOLIC PARAMETERS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DRUG THERAPY, COMBINATION; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; PROSPECTIVE STUDIES; PYRIMIDINES; RAMIPRIL; SULFONAMIDES; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84862220556     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.01.030     Document Type: Article

References (28)

1. Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
2. S. Yusuf, P. Sleight, and J. Pogue Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
3. K.K. Koh Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability Cardiovasc Res 47 2000 648 657
4. T.J. Anderson, I.T. Meredith, and A.C. Yeung The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent vasomotion N Engl J Med 332 1995 488 493
5. 1-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis Circulation 105 2002 393 396
6. Z. Li, M. Iwai, and L. Wu Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis Hypertension 44 2004 758 763
7. J. Chen, D. Li, and R.F. Schaefer Inhibitory effect of candesartan and rosuvastatin on CD40 and MMPs expression in apo-E knockout mice: novel insights into the role of RAS and dyslipidemia in atherogenesis J Cardiovasc Pharmacol 44 2004 446 452
8. K.K. Koh, M.J. Quon, and S.H. Han Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients Circulation 110 2004 3687 3692
9. S.H. Han, K.K. Koh, and M.J. Quon The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients Atherosclerosis 190 2007 205 211
10. K.K. Koh, P.C. Oh, and M.J. Quon Does reversal of oxidative stress and inflammation provide vascular protection? Cardiovasc Res 81 2009 649 659
11. J. Chen, D. Li, and R. Schaefer Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan Atherosclerosis 184 2006 295 301
12. M.J. Ricciardi, S. Meyers, and K. Choi Angiographically silent left main disease detected by intravascular ultrasound: a marker for future adverse cardiac events Am Heart J 146 2003 507 512
13. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 2004 1071 1080
14. G.S. Mintz, S.E. Nissen, and W.D. Anderson American College of Cardiology Clinical Expert Consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS): a report of the American College Of Cardiology Task Force on Clinical Expert Consensus documents developed in collaboration with the European Society of Cardiology endorsed by the Society of Cardiac Angiograpy and Interventions J Am Coll Cardiol 37 2001 478 492
15. A. Katz, S.S. Nambi, and K. Mather Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans J Clin Endocrinol Metab 85 2000 2402 2410
16. P. Scholenhagen, M. Tuzcu, and C. Apperson-Hansen Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis With Aggressive Lipid Lowering Therapy (REVERSAL) trial Circulation 113 2006 2826 2834
17. S.E. Nissen, S.J. Nicholls, and I. Sipahi ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial JAMA 295 2006 1556 1565
18. T. Takayama, T. Hiro, and M. Yamagishi COSMOS Investigators. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS) Circ J 73 2009 2110 2117
19. D. Weiss, J.J. Kools, and W.R. Taylor Angiotensin II-induced hypertension acceleaates the development of atherosclerosis in apoE-deficient mice Circulation 103 2001 1970 1976
20. K.K. Teo, J.R. Burton, and C.E. Buller et al.; for the SCAT investigators. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Circulation 102 2000 1748 1754
21. P.M. Ridker, N. Rifai, and L. Rose Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 2002 1557 1565
22. P.M. Ridker, C.H. Hennekens, and J.E. Buring C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women N Engl J Med 342 2000 836 843
23. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease N Engl J Med 352 2005 29 38
24. P.M. Ridker, C.P. Cannon, and D. Morrow Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy N Engl J Med 352 2005 20 28
25. E. Zouridakis, P. Avanzas, and R. Arroyo-Espliguero Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris Circulation 110 2004 1747 1753
26. T. Nakachi, M. Kosuge, and K. Hibi C-reactive protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment elevation acute coronary syndrome Circ J 72 2008 1953 1959
27. J.M. Tobis, and A. Perlowsk Atheroma volume by intravascular ultrasound as a surrogate for clinical end points J Am Coll Cardiol 53 2009 1116 1118
28. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 131 2009 149 150